| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2006-08-16 15:10:22 UTC |
|---|
| Update Date | 2022-03-07 02:49:10 UTC |
|---|
| HMDB ID | HMDB0001449 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Allopregnanolone |
|---|
| Description | Allopregnanolone is a neuroactive metabolite of progesterone and a barbiturate-like modulator of central gamma-aminobutyric acid receptors that modify a range of behaviors, including the stress response. is a steroid created in the body when progesterone, the female sex hormone, is metabolized. Typically, THP (allopregnanolone) is released in the brain in response to stress, and quiets the neural system within 30 minutes of escalation. This steroid hormone has recently been found to be responsible for the extreme mood swings found in teenagers. In adults and pre-pubescent chlidren THP normally helps soothe the activity of brain cells by binding to GABA receptors that inhibit accelerating electrical activity. However, in pubescent teenagers THP actually becomes a GABA receptor antagonist. GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the brain with most sedatives (tranquilizers, anesthetics and alcohol) acting on the GABA receptor. |
|---|
| Structure | [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (3alpha,5alpha)-3-Hydroxypregnan-20-one | ChEBI | | 3alpha,5alpha-Tetrahydroprogesterone | ChEBI | | 3alpha,5alpha-THP | ChEBI | | 3alpha-Hydroxy-5alpha-dihydroprogesterone | ChEBI | | 3alpha-Hydroxy-5alpha-pregnan-20-one | ChEBI | | 3alpha-OH DHP | ChEBI | | 5alpha-Pregnan-3alpha-ol-20-one | ChEBI | | Allopregnan-3alpha-ol-20-one | ChEBI | | Allotetrahydroprogesterone | ChEBI | | Brexanolona | ChEBI | | Brexanolonum | ChEBI | | SAGE-547 | ChEBI | | SGE-102 | ChEBI | | Zulresso | ChEBI | | (3a,5a)-3-Hydroxypregnan-20-one | Generator | | (3Α,5α)-3-hydroxypregnan-20-one | Generator | | 3a,5a-Tetrahydroprogesterone | Generator | | 3Α,5α-tetrahydroprogesterone | Generator | | 3a,5a-THP | Generator | | 3Α,5α-THP | Generator | | 3a-Hydroxy-5a-dihydroprogesterone | Generator | | 3Α-hydroxy-5α-dihydroprogesterone | Generator | | 3a-Hydroxy-5a-pregnan-20-one | Generator | | 3Α-hydroxy-5α-pregnan-20-one | Generator | | 3a-OH DHP | Generator | | 3Α-OH DHP | Generator | | 5a-Pregnan-3a-ol-20-one | Generator | | 5Α-pregnan-3α-ol-20-one | Generator | | Allopregnan-3a-ol-20-one | Generator | | Allopregnan-3α-ol-20-one | Generator | | (+)-3a-Hydroxy-5a-pregnan-20-one | HMDB | | (3a)-Allopregnanolone | HMDB | | 3-a-Tetrahydroprogesterone | HMDB | | 3-alpha-Tetrahydroprogesterone | HMDB | | 3a,5a-Pregnanolone | HMDB | | 3a-Hydroxy-5a-pregnane-20-one | HMDB | | 5a-Pregnane-3a-ol-20-one | HMDB | | 3-Hydroxypregnan-20-one | HMDB | | alpha-Hydroxy-5 alpha-pregnan-20-one, 3 | HMDB | | Pregnan-3alpha-ol-20-one | HMDB | | Pregnanolone, (3alpha)-isomer | HMDB | | 3 Hydroxypregnan 20 one | HMDB | | 3 alpha Hydroxy 5 alpha pregnan 20 one | HMDB | | 3 alpha-Hydroxy-5 alpha-pregnan-20-one | HMDB | | Pregnan 3alpha ol 20 one | HMDB | | alpha-Pregnan-20-one, 3 alpha-hydroxy-5 | HMDB | | (+)-3alpha-Hydroxy-5alpha-pregnan-20-one | HMDB | | (+)-3Α-hydroxy-5α-pregnan-20-one | HMDB | | (3alpha)-Allopregnanolone | HMDB | | (3Α)-allopregnanolone | HMDB | | 3alpha,5alpha-Pregnanolone | HMDB | | 3alpha-Hydroxy-5alpha-pregnane-20-one | HMDB | | 3Α,5α-pregnanolone | HMDB | | 3Α-hydroxy-5α-pregnane-20-one | HMDB | | 5alpha-Pregnane-3alpha-ol-20-one | HMDB | | 5Α-pregnane-3α-ol-20-one | HMDB | | Allopregnanolone | MeSH, ChEBI |
|
|---|
| Chemical Formula | C21H34O2 |
|---|
| Average Molecular Weight | 318.4935 |
|---|
| Monoisotopic Molecular Weight | 318.255880332 |
|---|
| IUPAC Name | 1-[(1S,2S,5R,7S,10R,11S,14S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]ethan-1-one |
|---|
| Traditional Name | 1-[(1S,2S,5R,7S,10R,11S,14S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]ethanone |
|---|
| CAS Registry Number | 516-54-1 |
|---|
| SMILES | [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O |
|---|
| InChI Identifier | InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1 |
|---|
| InChI Key | AURFZBICLPNKBZ-SYBPFIFISA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Pregnane steroids |
|---|
| Direct Parent | Gluco/mineralocorticoids, progestogins and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Progestogin-skeleton
- 20-oxosteroid
- 3-hydroxysteroid
- Hydroxysteroid
- 3-alpha-hydroxysteroid
- Oxosteroid
- Cyclic alcohol
- Ketone
- Secondary alcohol
- Organooxygen compound
- Hydrocarbon derivative
- Organic oxide
- Organic oxygen compound
- Carbonyl group
- Alcohol
- Aliphatic homopolycyclic compound
|
|---|
| Molecular Framework | Aliphatic homopolycyclic compounds |
|---|
| External Descriptors | - 3-hydroxy-5alpha-pregnan-20-one (CHEBI:50169 )
- C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030156 )
|
|---|
| Ontology |
|---|
| Physiological effect | |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 177 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.74 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 17.457 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.03 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2755.4 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 444.8 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 225.5 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 194.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 527.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 719.8 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 706.8 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 102.5 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1346.5 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 495.6 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1610.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 419.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 466.4 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 263.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 443.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 12.6 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Allopregnanolone,1TMS,isomer #1 | CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O[Si](C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 2738.7 | Semi standard non polar | 33892256 | | Allopregnanolone,1TMS,isomer #2 | CC(O[Si](C)(C)C)=C1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C | 2783.9 | Semi standard non polar | 33892256 | | Allopregnanolone,1TMS,isomer #3 | C=C(O[Si](C)(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C | 2734.6 | Semi standard non polar | 33892256 | | Allopregnanolone,2TMS,isomer #1 | CC(O[Si](C)(C)C)=C1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O[Si](C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 2787.6 | Semi standard non polar | 33892256 | | Allopregnanolone,2TMS,isomer #1 | CC(O[Si](C)(C)C)=C1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O[Si](C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 2777.0 | Standard non polar | 33892256 | | Allopregnanolone,2TMS,isomer #1 | CC(O[Si](C)(C)C)=C1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O[Si](C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3133.8 | Standard polar | 33892256 | | Allopregnanolone,2TMS,isomer #2 | C=C(O[Si](C)(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O[Si](C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 2760.9 | Semi standard non polar | 33892256 | | Allopregnanolone,2TMS,isomer #2 | C=C(O[Si](C)(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O[Si](C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 2765.2 | Standard non polar | 33892256 | | Allopregnanolone,2TMS,isomer #2 | C=C(O[Si](C)(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O[Si](C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3230.8 | Standard polar | 33892256 | | Allopregnanolone,1TBDMS,isomer #1 | CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 2985.7 | Semi standard non polar | 33892256 | | Allopregnanolone,1TBDMS,isomer #2 | CC(O[Si](C)(C)C(C)(C)C)=C1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C | 3032.5 | Semi standard non polar | 33892256 | | Allopregnanolone,1TBDMS,isomer #3 | C=C(O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C | 2995.8 | Semi standard non polar | 33892256 | | Allopregnanolone,2TBDMS,isomer #1 | CC(O[Si](C)(C)C(C)(C)C)=C1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3282.4 | Semi standard non polar | 33892256 | | Allopregnanolone,2TBDMS,isomer #1 | CC(O[Si](C)(C)C(C)(C)C)=C1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3254.0 | Standard non polar | 33892256 | | Allopregnanolone,2TBDMS,isomer #1 | CC(O[Si](C)(C)C(C)(C)C)=C1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3369.8 | Standard polar | 33892256 | | Allopregnanolone,2TBDMS,isomer #2 | C=C(O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3288.7 | Semi standard non polar | 33892256 | | Allopregnanolone,2TBDMS,isomer #2 | C=C(O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3256.2 | Standard non polar | 33892256 | | Allopregnanolone,2TBDMS,isomer #2 | C=C(O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3436.2 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental GC-MS | GC-MS Spectrum - Allopregnanolone GC-MS (1 MEOX; 1 TMS) | splash10-0udi-6910000000-837b37f206729753b640 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Allopregnanolone GC-MS (Non-derivatized) | splash10-0udi-6910000000-837b37f206729753b640 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Allopregnanolone GC-MS (Non-derivatized) - 70eV, Positive | splash10-1174-0292000000-fb2c0f3a1cfddb10cb08 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Allopregnanolone GC-MS (1 TMS) - 70eV, Positive | splash10-004i-2139000000-ab8a6de8f5a129af086e | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Allopregnanolone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Allopregnanolone 10V, Positive-QTOF | splash10-0uxr-0129000000-90e5fcb36022dd1ba688 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Allopregnanolone 20V, Positive-QTOF | splash10-0uxr-0396000000-4c39fe7ccd8e0c86e179 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Allopregnanolone 40V, Positive-QTOF | splash10-0006-2490000000-7ac55935cc0d4da95860 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Allopregnanolone 10V, Negative-QTOF | splash10-014i-0029000000-fa09e69c9c0b6736d2e7 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Allopregnanolone 20V, Negative-QTOF | splash10-014i-0069000000-d1d57e3e1a99da4ed11f | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Allopregnanolone 40V, Negative-QTOF | splash10-0zg0-1193000000-44d1597a59ac11f16a41 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Allopregnanolone 10V, Positive-QTOF | splash10-0gb9-0019000000-5b53b3ba37ccafca449f | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Allopregnanolone 20V, Positive-QTOF | splash10-0lgi-1797000000-c11629ffa10cac4be118 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Allopregnanolone 40V, Positive-QTOF | splash10-0a4m-8910000000-2813a600e98ff5997275 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Allopregnanolone 10V, Negative-QTOF | splash10-014i-0009000000-bbaa566ea695ae62f84e | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Allopregnanolone 20V, Negative-QTOF | splash10-014i-0029000000-ac1c6a15538469151b6c | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Allopregnanolone 40V, Negative-QTOF | splash10-00ks-0093000000-db70f670eb2440b743f9 | 2021-09-25 | Wishart Lab | View Spectrum |
|
|---|
| Disease References | | Alcoholism |
|---|
- Nieminen LR, Makino KK, Mehta N, Virkkunen M, Kim HY, Hibbeln JR: Relationship between omega-3 fatty acids and plasma neuroactive steroids in alcoholism, depression and controls. Prostaglandins Leukot Essent Fatty Acids. 2006 Oct-Nov;75(4-5):309-14. Epub 2006 Sep 7. [PubMed:16959481 ]
| | Prepartum depression |
|---|
- Pearson Murphy BE, Steinberg SI, Hu FY, Allison CM: Neuroactive ring A-reduced metabolites of progesterone in human plasma during pregnancy: elevated levels of 5 alpha-dihydroprogesterone in depressed patients during the latter half of pregnancy. J Clin Endocrinol Metab. 2001 Dec;86(12):5981-7. [PubMed:11739473 ]
| | Major depressive disorder |
|---|
- Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A: Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3239-44. [PubMed:9501247 ]
- Nieminen LR, Makino KK, Mehta N, Virkkunen M, Kim HY, Hibbeln JR: Relationship between omega-3 fatty acids and plasma neuroactive steroids in alcoholism, depression and controls. Prostaglandins Leukot Essent Fatty Acids. 2006 Oct-Nov;75(4-5):309-14. Epub 2006 Sep 7. [PubMed:16959481 ]
|
|
|---|